Xylo Bio

🚨 We’re officially Xylo Bio!

New name, sharper focus: advancing neuroplastogens to restore brain function.

XYL-1001 moves toward clinical trials + new board members. We’re entering an exciting new chapter!

📢 Read more: prnewswire.com/news-releases/…

#Biotech #Neurotherapeutics

Our November newsletter covers EEG - a way to measure brain activity via electric signals.

This measure has been used to identify signatures related to various disease states & more recently is being applied to #drugdevelopment in #neuropsychiatry.

xylo.bio/blog-posts/nov…

Give our October Newsletter a read!

Here we explore the brain’s remarkable adaptability in our Science in Sixty Seconds spotlight on neuroplasticity, company updates + recent research.

xylo.bio/blog-posts/oct…

It’s been a while… 👋

We’ve been hard at work on creating the next first-in-class neurotherapeutics but now we’re back on X!

We’ll be sharing our newsletter & key updates, for more frequent updates be sure to follow us on LinkedIn!

🧠 We're excited to attend the Gordon Research Conference on the Neurobiology of Psychedelics next week in RI!

We'll be presenting new data on 5-Me0-DMT analogues as novel antidepressants.

We look forward to connecting with peers and exploring the latest science! @samuel_b_phd